Your browser doesn't support javascript.
loading
Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
Garg, Aakash; Rout, Amit; Sharma, Abhishek; Sargsyan, Davit; Beavers, Traymon; Tantry, Udaya; Gurbel, Paul; Rao, Sunil V; Kostis, John B; Cohen, Marc.
Afiliación
  • Garg A; Division of Cardiology, Newark Beth Israel Medical Center, NJ, USA; Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, NJ, USA.
  • Rout A; Department of Medicine, Sinai Hospital, Baltimore, MD, USA.
  • Sharma A; Section of Cardiovascular Medicine, Gundersen Health System, WI, USA. Electronic address: abhisheksharma4mamc@gmail.com.
  • Sargsyan D; Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, NJ, USA.
  • Beavers T; Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, NJ, USA.
  • Tantry U; Department of Medicine, Sinai Hospital, Baltimore, MD, USA.
  • Gurbel P; Department of Medicine, Sinai Hospital, Baltimore, MD, USA.
  • Rao SV; Duke Clinical Research Institute, Durham, NC, USA.
  • Kostis JB; Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, NJ, USA.
  • Cohen M; Division of Cardiology, Newark Beth Israel Medical Center, NJ, USA.
Prog Cardiovasc Dis ; 63(3): 243-248, 2020.
Article en En | MEDLINE | ID: mdl-32247786
AIMS: We aimed to determine the efficacy and safety of different anti-platelet regimens after percutaneous coronary intervention (PCI) with drug eluting stent (DES) implantation using a network meta-analysis of randomized controlled trials (RCTs). METHODS: RCTs comparing shorter duration (≤6 months) of dual antiplatelet therapy (S-DAPT) with either aspirin (ASA) or P2Y12 inhibitor monotherapy against longer duration (≥12 months) DAPT (L-DAPT) after PCI were searched in the MEDLINE, EMBASE and COCHRANE databases. End-points of interest were all-cause death, cardiovascular (CV) death, myocardial infarction (MI), stent thrombosis (ST), major bleeding and major or minor bleeding. Network meta-analyses were performed using frequentist approach. RESULTS: Eighteen RCTs with total of 57,942 patients met the inclusion and exclusion criteria. This included 14 RCTs (N = 28,853) of S-DAPT with ASA monotherapy and 4 RCTs (N = 29,089) with P2Y12 inhibitor monotherapy. Compared with L-DAPT, the odds of MI were higher with S-DAPT with ASA monotherapy [OR 1.23; 95% CI 1.01-1.48], but not with P2Y12 inhibitor monotherapy [0.98; 0.85-1.14]. Both S-DAPT regimens lowered rates of major bleeding when compared with L-DAPT; ASA monotherapy [0.70; 0.49-1.00] and P2Y12 monotherapy [0.67; 0.45-0.98]. There were no differences in risks of all-cause or CV death between either regimen of S-DAPT and L-DAPT. However, in the acute coronary syndrome subgroup, ASA monotherapy was associated with increased risk of ST [1.55; 1.021-2.36] but P2Y12 monotherapy was not [0.93; 0.58-1.48]. CONCLUSION: Amongst patients undergoing DES implantation, S-DAPT with P2Y12 inhibitor monotherapy reduces bleeding without increased risk of MI or ST compared with L-DAPT. Prospective trials are needed to evaluate if S-DAPT with P2Y12 monotherapy is superior to S-DAPT with ASA monotherapy for ischemic protection.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles / 6_cardiovascular_diseases / 6_ischemic_heart_disease Asunto principal: Enfermedad de la Arteria Coronaria / Inhibidores de Agregación Plaquetaria / Stents Liberadores de Fármacos / Intervención Coronaria Percutánea / Terapia Antiplaquetaria Doble Tipo de estudio: Clinical_trials / Etiology_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Prog Cardiovasc Dis Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles / 6_cardiovascular_diseases / 6_ischemic_heart_disease Asunto principal: Enfermedad de la Arteria Coronaria / Inhibidores de Agregación Plaquetaria / Stents Liberadores de Fármacos / Intervención Coronaria Percutánea / Terapia Antiplaquetaria Doble Tipo de estudio: Clinical_trials / Etiology_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Prog Cardiovasc Dis Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
...